SG11202111262XA - Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer - Google Patents
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancerInfo
- Publication number
- SG11202111262XA SG11202111262XA SG11202111262XA SG11202111262XA SG11202111262XA SG 11202111262X A SG11202111262X A SG 11202111262XA SG 11202111262X A SG11202111262X A SG 11202111262XA SG 11202111262X A SG11202111262X A SG 11202111262XA SG 11202111262X A SG11202111262X A SG 11202111262XA
- Authority
- SG
- Singapore
- Prior art keywords
- inhibitors
- lag
- combination
- treating cancer
- enhanced efficacy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962847068P | 2019-05-13 | 2019-05-13 | |
PCT/US2020/032515 WO2020232019A1 (en) | 2019-05-13 | 2020-05-12 | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202111262XA true SG11202111262XA (en) | 2021-11-29 |
Family
ID=71069936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202111262XA SG11202111262XA (en) | 2019-05-13 | 2020-05-12 | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220249659A1 (en) |
EP (1) | EP3969040A1 (en) |
JP (1) | JP2022532490A (en) |
KR (1) | KR20220007593A (en) |
CN (1) | CN113825527A (en) |
AU (1) | AU2020276242A1 (en) |
BR (1) | BR112021021713A2 (en) |
CA (1) | CA3136568A1 (en) |
CL (1) | CL2021002966A1 (en) |
EA (1) | EA202192528A1 (en) |
IL (1) | IL287728A (en) |
MA (1) | MA55965A (en) |
MX (1) | MX2021013815A (en) |
SG (1) | SG11202111262XA (en) |
WO (1) | WO2020232019A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3156227A1 (en) * | 2019-11-04 | 2021-05-14 | Amy-Lee BREDLAU | Combination therapy to treat brain cancer |
WO2023010095A1 (en) * | 2021-07-28 | 2023-02-02 | F. Hoffmann-La Roche Ag | Methods and compositions for treating cancer |
CN115869399B (en) * | 2022-12-28 | 2024-01-12 | 广州誉衡生物科技有限公司 | Pharmaceutical composition and pharmaceutical preparation and application thereof in treating non-small cell lung cancer |
CN115845052B (en) * | 2022-12-28 | 2023-12-29 | 广州誉衡生物科技有限公司 | Pharmaceutical composition and pharmaceutical preparation and application thereof in treating colon cancer |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
FR2656800B1 (en) | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | NEW PROTEINS PRODUCED BY HUMAN LYMPHOCYTES, DNA SEQUENCE ENCODING THESE PROTEINS AND PHARMACEUTICAL AND BIOLOGICAL APPLICATIONS. |
US5976877A (en) | 1990-01-08 | 1999-11-02 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Proteins produced by human lymphocytes DNA sequence encoding these proteins and their pharmaceutical and biological uses |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
IL113617A (en) | 1994-05-06 | 2007-09-20 | Florence Faure | Use of antibodies against lag-3 for the preparation of an immunostimulatory therapeutic composition |
US5532210A (en) | 1994-06-08 | 1996-07-02 | E. I. Du Pont De Nemours And Company | High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes |
JP2000508226A (en) | 1995-07-21 | 2000-07-04 | アプライド リサーチ システムズ アース ホールディング エヌ.ヴィ. | Method for detecting, identifying, isolating, and selectively labeling and targeting TH1 lymphocytes with LAG-3 protein |
EP0900841A1 (en) | 1997-06-18 | 1999-03-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | LAG-3 splice variants |
EP1135415B1 (en) | 1998-12-01 | 2010-08-11 | Facet Biotech Corporation | Humanized antibodies to gamma-interferon |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
BR0013581A (en) | 1999-08-23 | 2002-07-02 | Dana Faber Cancer Inst Inc | Pd-1, a receiver for b7-4, and uses for it |
JP4511943B2 (en) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Antibody against PD-1 and use thereof |
ES2439580T3 (en) | 2003-02-28 | 2014-01-23 | The Johns Hopkins University | T cell regulation |
JP5252922B2 (en) | 2004-10-19 | 2013-07-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Methods for generating homozygous animals for genetic modification |
EP2418278A3 (en) | 2005-05-09 | 2012-07-04 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
EP3222634A1 (en) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
PT2242773T (en) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Monoclonal antibodies for tumor treatment |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
AR072999A1 (en) | 2008-08-11 | 2010-10-06 | Medarex Inc | HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE |
RS54233B1 (en) | 2008-08-25 | 2015-12-31 | Amplimmune Inc. | Compositions of pd-1 antagonists and methods of use |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
PL2699264T3 (en) | 2011-04-20 | 2018-08-31 | Medimmune, Llc | Antibodies and other molecules that bind b7-h1 and pd-1 |
EP2734551B1 (en) | 2011-07-24 | 2018-01-10 | Cure Tech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
UY34887A (en) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES |
UA118750C2 (en) | 2013-03-15 | 2019-03-11 | Ґлаксосмітклайн Інтеллектуал Проперті Дивелопмент Лімітед | Anti-lag-3 binding proteins |
SG11201601763SA (en) * | 2013-09-20 | 2016-04-28 | Bristol Myers Squibb Co | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
DK3254110T3 (en) | 2015-02-03 | 2020-05-18 | Ventana Med Syst Inc | Histochemical test to assess programmed death ligand 1 expression (pd-l1) |
WO2016191751A1 (en) | 2015-05-28 | 2016-12-01 | Bristol-Myers Squibb Company | Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody |
EP3798234A1 (en) | 2015-09-02 | 2021-03-31 | Immutep S.A.S. | Anti-lag-3 agonistic antibodies |
TWI756187B (en) * | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | Anti-lag3 antibodies and uses thereof |
TWI822521B (en) * | 2016-05-13 | 2023-11-11 | 美商再生元醫藥公司 | Methods of treating skin cancer by administering a pd-1 inhibitor |
AU2017266298B2 (en) * | 2016-05-18 | 2024-01-04 | Boehringer Ingelheim International Gmbh | Anti PD-1 and anti-LAG3 antibodies for cancer treatment |
CN117586403A (en) | 2016-10-11 | 2024-02-23 | 艾吉纳斯公司 | anti-LAG-3 antibodies and methods of use thereof |
CN117567623A (en) | 2016-10-13 | 2024-02-20 | 正大天晴药业集团股份有限公司 | anti-LAG-3 antibodies and compositions |
MX2019006448A (en) | 2016-12-01 | 2020-02-05 | Regeneron Pharma | Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging. |
KR20240058959A (en) | 2017-02-10 | 2024-05-07 | 리제너론 파마슈티칼스 인코포레이티드 | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
US11939380B2 (en) * | 2017-04-05 | 2024-03-26 | Les Laboratoires Servier | Combination therapies targeting PD-1, TIM-3, and LAG-3 |
-
2020
- 2020-05-12 JP JP2021563296A patent/JP2022532490A/en active Pending
- 2020-05-12 MX MX2021013815A patent/MX2021013815A/en unknown
- 2020-05-12 SG SG11202111262XA patent/SG11202111262XA/en unknown
- 2020-05-12 AU AU2020276242A patent/AU2020276242A1/en active Pending
- 2020-05-12 CN CN202080035740.2A patent/CN113825527A/en active Pending
- 2020-05-12 WO PCT/US2020/032515 patent/WO2020232019A1/en unknown
- 2020-05-12 EP EP20731629.0A patent/EP3969040A1/en active Pending
- 2020-05-12 EA EA202192528A patent/EA202192528A1/en unknown
- 2020-05-12 KR KR1020217034542A patent/KR20220007593A/en unknown
- 2020-05-12 BR BR112021021713A patent/BR112021021713A2/en unknown
- 2020-05-12 CA CA3136568A patent/CA3136568A1/en active Pending
- 2020-05-12 MA MA055965A patent/MA55965A/en unknown
- 2020-05-12 US US17/611,073 patent/US20220249659A1/en active Pending
-
2021
- 2021-10-31 IL IL287728A patent/IL287728A/en unknown
- 2021-11-10 CL CL2021002966A patent/CL2021002966A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3136568A1 (en) | 2020-11-19 |
BR112021021713A2 (en) | 2022-04-19 |
MA55965A (en) | 2022-03-23 |
US20220249659A1 (en) | 2022-08-11 |
MX2021013815A (en) | 2021-12-14 |
CN113825527A (en) | 2021-12-21 |
AU2020276242A1 (en) | 2021-12-02 |
IL287728A (en) | 2021-12-01 |
EP3969040A1 (en) | 2022-03-23 |
WO2020232019A1 (en) | 2020-11-19 |
JP2022532490A (en) | 2022-07-15 |
CL2021002966A1 (en) | 2022-08-26 |
KR20220007593A (en) | 2022-01-18 |
EA202192528A1 (en) | 2022-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL287728A (en) | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer | |
IL277665A (en) | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
SG11202001282UA (en) | Shp2 inhibitor compositions and methods for treating cancer | |
IL284326A (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
IL284324A (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
IL288395A (en) | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
MX2018014435A (en) | Pd-1 / pd-l1 inhibitors for cancer treatment. | |
IL277918A (en) | Combination of lif inhibitors and pd-1 axis inhibitors for use in treating cancer | |
HK1244436A1 (en) | Combination therapy of hsp90 inhibitors and pd-1 inhibitors for treating cancer | |
IL287043A (en) | Inhibitors of notch signalling pathway and use thereof in treatment of cancers | |
EP3576766A4 (en) | Cyclin g1 inhibitors and related methods of treating cancer | |
IL304294A (en) | Pharmaceutical combinations of sos1 inhibitors for treating and/or preventing cancer | |
IL282654A (en) | Method and medicament for treating cancer unresponsive to pd-1/pd-l1 signaling inhibitor | |
ZA201901367B (en) | Inhibition of olig2 activity | |
WO2017019721A3 (en) | Combinations of ezh2 inhibitors with further agents for use in the treatment of cancer | |
BR112022008295A2 (en) | COMBINED INHIBITION OF PD-1, TGFBETA AND TIGIT FOR THE TREATMENT OF CANCER | |
IL270948A (en) | Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer | |
EP4110822A4 (en) | Compositions and methods for treating cancer | |
EP4127722A4 (en) | Methods and compositions for treating cancer | |
SG11202108089SA (en) | Administration of pd-1 inhibitors for treating skin cancer | |
WO2021067572A3 (en) | Compositions and methods for inhibiting carp-1 binding to nemo | |
EP4136072A4 (en) | Compositions and methods for treating pain and/or inflammation | |
GB201709076D0 (en) | Parp inhibitors for use in methods of treating cancer | |
GB202402730D0 (en) | Methods and compositions for treating cancer | |
HUP1900281A1 (en) | Use of monoamine-oxidase-b inhibitors in the prevention or treatment of prostate cancer |